Stockholm, Sweden, February 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today proudly announced that CEO, Gunilla Osswald, has been awarded the Arthur D. Little Nordic Life Science Award. This recognition is given to individuals in the Nordic region who demonstrate extraordinary leadership within the Life Science industry.
The jury cited Gunilla Osswald’s “high-caliber leadership qualities” as the foundation for her award, highlighting her ability to foster “a shared ambition, inclusiveness, and sense of purpose” throughout the company and with stakeholders. These efforts have been instrumental in establishing BioArctic as a global frontrunner in the field of neurodegenerative disease research and treatment.
Gunilla Osswald shared her thoughts on receiving the award: “It is a great honor to receive this award, which reflects not only my own efforts but the collective hard work and dedication of the entire BioArctic team. Our mission to deliver innovative treatments for patients suffering from neurodegenerative diseases drives us every day, and this award further supports our important work.”
BioArctic is dedicated to improving the quality of life for patients affected by conditions such as Alzheimer’s disease, Parkinson’s disease and ALS.
The Arthur D. Little Nordic Life Science Award is a testament to leadership excellence within the Nordic life sciences community. BioArctic is thrilled that Gunilla Osswald’s visionary and inspiring leadership is recognized and that the company’s innovations to help patients are continuously acknowledged.
—
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
Jiang Millington, Director Corporate Communication and Social Media
E-mail: jiang.millington@bioarctic.se
Phone: +46 79 33 99 166
This information was submitted for publication at 08:00 CET on February 22, 2024.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.